Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Non-Current Assets (2021 - 2025)

Prime Medicine filings provide 5 years of Non-Current Assets readings, the most recent being $161.4 million for Q4 2025.

  • On a quarterly basis, Non-Current Assets rose 88.55% to $161.4 million in Q4 2025 year-over-year; TTM through Dec 2025 was $637.2 million, a 79.5% increase, with the full-year FY2025 number at $161.4 million, up 88.55% from a year prior.
  • Non-Current Assets hit $161.4 million in Q4 2025 for Prime Medicine, up from $153.6 million in the prior quarter.
  • In the past five years, Non-Current Assets ranged from a high of $164.4 million in Q1 2025 to a low of $31.3 million in Q4 2021.
  • Median Non-Current Assets over the past 5 years was $85.6 million (2024), compared with a mean of $92.3 million.
  • Biggest five-year swings in Non-Current Assets: surged 103.65% in 2022 and later decreased 20.13% in 2023.
  • Prime Medicine's Non-Current Assets stood at $31.3 million in 2021, then soared by 103.65% to $63.7 million in 2022, then dropped by 20.13% to $50.9 million in 2023, then soared by 68.3% to $85.6 million in 2024, then surged by 88.55% to $161.4 million in 2025.
  • The last three reported values for Non-Current Assets were $161.4 million (Q4 2025), $153.6 million (Q3 2025), and $157.7 million (Q2 2025) per Business Quant data.